GHSR and obesity due to melanocortin 4 receptor deficiency: Thus, GHS-R1a agonists or antagonists may serve as novel and effective therapeutic options for many syndromes and diseases, such as cancer cachexia, aging-related cognitive decline, obesity, and diabetes [74].